ALGENEX S.L

We are experts in developing novel sub-unit vaccines Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platforms potential. CrisBio also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner. Our current portfolio comprises 6 vaccines across livestock species. Proof of concepts have been generated in > 20 additional vaccine antigens Value through collaborations Our go to market strategy is inherently linked to collaborations. We offer: Development of tailor-made baculovirus vectors optimized for industrial production. Proof-of-concept studies to validate the production of recombinant proteins in CrisBio. Supply of recombinant proteins produced in CrisBio through license agreements. Development of proprietary portfolios. Algenex is led by an internationally experienced management team, ...